The procedures required for reimbursement are as follows:
1, inpatient medical records
2. Cost list
3. Hospitalization invoice
4, discharge summary
4. Disease diagnosis
5. ID card and household registration book
6, cooperative medical book (or card, card)
7. Transfer procedures or certificates (work certificate or emergency certificate of the unit). Outpatients take medicine outside the hospital at their own expense. But in one case, they can go to the hospital for reimbursement after seeing a doctor, and the hospital has built a special seal for outsourcing. With this prescription, they can buy medicine at the designated pharmacy, and the medicine fee can be reimbursed. However, the selected pharmacy must be qualified as a designated pharmacy for basic medical insurance, otherwise it will not be reimbursed. Oil and tolls can be reported, and the tax bureau should not be so boring. Moreover, just because I don't have a car doesn't mean I can't borrow or rent a car, and gas and tolls will also happen. But repair and nursing expenses (I guess you mean maintenance and insurance) should not be reported. At the very least, the invoices for those expenses should have the driving number or the owner's name, which has nothing to do with your company. Before Hengrui, the share prices of almost all pharmaceutical companies whose product prices dropped sharply due to centralized procurement would fall sharply in the next period of time, but after the price reduction of core products, Hengrui's share price rose by nearly 20%, which once again proved this point.
The lethality of medical insurance negotiation to Hengrui is not as good as that of centralized procurement to other generic drug companies, because the decline is relatively small. Compared with the 95% decline of generic drugs, the 85% decline of Karelizumab is moderate, which is better than the previous market consensus. Moreover, after entering the medical insurance, the previous drug donation link may be cancelled, which has little impact on the price of Hengrui.
Secondly, high-priced innovative drugs enter the medical insurance through negotiation, which greatly stimulates sales, and pharmaceutical companies can get the return of exchanging quantity for price. Since innovative drugs are much higher than the extremely high gross profit margin of generic drugs, the increase in sales will help the performance more than generic drugs.
For example, 20 19+0 1 The only successful PD- 1 in the fourth round of medical insurance negotiation represents Xinda Pharmaceutical Xindili monoclonal antibody (daboshu). Before entering medical insurance, the sales volume in the first half of 20 19 was only 332 million, but by the first half of 2020, the sales volume has reached 9.265438+.
It is worth mentioning that Cindilizumab is only approved for one indication of Hodgkin's lymphoma, while Hengruikarizumab has all four indications of Hodgkin's lymphoma, hepatocellular carcinoma, non-small cell lung cancer and esophageal squamous cell carcinoma. In particular, non-small cell lung cancer and esophageal squamous cell carcinoma are the only approved varieties in domestic PD- 1. Lung cancer and esophageal cancer are both high-incidence cancers in China, with an annual incidence of about 700,000 and 400,000. Hengrui is obviously ahead in the market competition of PD- 1.
In the first half of 2020, the sales of Hengrui Karelizumab exceeded 2 billion, and it is expected to exceed 5 billion in the whole year. 202 1 is a crucial year for PD- 1. Hengrui has strong sales ability and wide indications. It should be promising for Karelizumab's sales to exceed 10 billion, which will bring more powerful impetus to Hengrui's performance growth this year.